上皮性卵巢癌组织中肺耐药蛋白的表达及意义

目的探讨上皮性卵巢癌中肺耐药蛋白(LRP)的表达及其临床意义。方法采用免疫组化SP法及半定量分析方法,检测上皮性卵巢癌64例,复发后二次手术癌组织17例,卵巢良性上皮性肿瘤16例及正常卵巢组织14例中LRP的表达,并进行相关临床病理因素分析。结果在上皮性卵巢癌中LRP的阳性率为78.1%,与卵巢良性肿瘤及正常卵巢有显著性差异(P<0.01);化疗后癌组织中LRP的强阳性表达率与初治卵巢癌组织中相应的表达率差异有显著性。结论LRP在上皮性卵巢癌中较恒定表达,化疗可以增加癌组织中LRP的表达。检测LRP表达水平可以预测卵巢癌对铂类联合化疗疗效,也是判断其预后的可靠指标之一。

Expression and significance of lung resistance protein in epithelial ovarian cancer

Objective: To determine the expression and significance of lung resistance protein (LRP) in epithelial ovarian cancer. Methods: The expression of LRP was assayed by means of SP immunohistochemical staining and semi-quantitative technique in 64 cases of epithelial ovarian cancer, in which 17 cases of cancer were recurrent samples; 16 cases of benign ovarian tumor and 14 normal ovaries. The results were analyzed in correlation with some clinicopathologic parameters. Results: The positive rate of LRP was 78.1% in epithelial ovarian cancer, evaluation of LRP revealed significant differences between the cancer and normal ovaries and benign ovarian tumors; the positive rate of LRP in cancer tissue from recurrent cancer showed a statistical difference with those in primary ovarian cancer. There was a significant reverse correlation between the expression of LRP and the prognosis of the patients. Conclusion: The expression of LRP could be promoted by platinum based chemotherapy in epithelial ovarian cancer, which may serve as reliable parameters of response to chemotherapy and prognosis.